Skip to main content

Table 1 Characteristics of included randomized controlled trials

From: Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review

StudyNo. of patientsStage of gastric cancerMTE (type and dose)Chemotherapy regimen for both groupsCo-intervention for side effectsLength of follow up (week)Outcome
MTE groupControl group
Deng 2016 [20]1515AdvancedMTE injection, 80 ml/d for 7 d, 2 sessionsTP5-HT3 antagonists6a,b,c
Gao 2015 [21]9291AdvancedMTE injection, 40 ml/d for 14 d, 2 sessionsXELOXTropisetron and CSF16a,c,d,e,g
Gao 2017 [22]3333IVMTE injection, 80 ml/d for 14 d, 4 sessionsTPNR12a,b,c,d,e,g
Huang 2013 [23]3636Early stage with radical gastrectomyMTE tablet, 2.4 g/time, 3 times/d for 30 d, 2 sessionsFOIFOX/XELOX/EOFNR26c,d,
Huo 2009 [24]3131AdvancedMTE tablet, 2.4 g/time, 3 times/d for 30 d, 2 sessionsFOIFOXGranisetron8a
Keyoumu 2012 [25]3335III and IVMTE injection, 60 ml/d for 7 d, 2 sessionsFOLFOXOndansetron14.2a,b,c,d,e,g,h
Li 2016 [26]6060IVMTE injection, 80 ml/d for 14 d, 4 sessionsCPT-11NR8a,c,e,g,h,i
Lin 2015 [27]2828AdvancedMTE injection, 60 ml/d for 14 d, 2 sessionsXELOXTropisetron, metoclopramide, vitamin B6, and CSF6a,b,c,d,e,f,g,i
Liu 2012 [28]2828IVMTE injection, 80 ml/d for 7 d, 4 sessionsFOLFOX5-HT3 antagonists8a,c,d,e,f,g
Liu 2017 [29]4848III and IVMTE injection, 60 ml/d for 14 d, 2 sessionsSOXPalonosetron and metoclopramide12a,b,c,d,g,h,i
Ma 2015 [30]2323AdvancedMTE injection, 60 ml/d for 7 d, 2 sessionsSOXNR6b,c
Shi 2017 [31]5353Early stage with radical gastrectomyMTE tablet, 2.4 g/time, 3 times/d for 30 d, 2 sessionsEOF/OLFNR26c,d,
Xiong 2015 [32]3232IVMTE injection, 80 ml/d for 21 d, 4 sessionschemotherapyVitamin12a,g,i,j
Zhang HY 2015 [33]4646III and IVMTE capsule, 2.0 g/time, 2 times/d for 30 d, 2 sessionsPFNR8a,b,c,d
Zhang H 2015 [34]2523AdvancedMTE injection, 40 ml/d for 14 d, 2 sessionsXELOXCSF6a,b,c,d,e,f,g,h
Zheng 2017 [35]4242III and IVMTE injection, 60 ml/d for 21 d, 2 sessionschemotherapyNR18a,c,d,e,g,h,i,j
Zhu 2017 [36]4040AdvancedMTE injection, 60 ml/d for 14 d, 4 sessionsFOLFOXTropisetron8a,c,d,e,g,h
  1. Abbreviations: T trial group; C control group; MTE Marsdenia tenacissima extract; NR not reported; FOLFOX folinic acid + fluorouracil + oxaliplatin; XELOX capecitabine + oxaliplatin; TP docetaxel + cisplatin; SOX S-1 + oxaliplatin; EOF epirubicin + oxaliplatin + fluorouracil; OLF oxaliplatin + leucovorin + flurouracil; CPT-11 irinotecan; PF cabazitaxel + Platinum + fluorouracil; CSF colony stimulating factor
  2. Outcomes: a = response to treatment; b = performance status; c = myelosuppression; d = gastrointestinal reactions; e = hepatic injury; f = kidney injury; g = neurotoxicity; h = oral mucosal lesions; i = progression-free survival; j = overall survival
\